社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
aiyohyun
IP属地：海外
+关注
帖子 · 217
帖子 · 217
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
aiyohyun
aiyohyun
·
2021-10-24
Ok
US IPO Week Ahead: Semiconductors, energy storage, designer apparel, and more in a 12 IPO week
The IPO market continues to stay busy with 12 IPOs schedule to raise $6.8 billion in the week ahead.
US IPO Week Ahead: Semiconductors, energy storage, designer apparel, and more in a 12 IPO week
看
2,050
回复
1
点赞
8
编组 21备份 2
分享
举报
aiyohyun
aiyohyun
·
2021-10-23
Ok
非常抱歉，此主贴已删除
看
2,737
回复
1
点赞
4
编组 21备份 2
分享
举报
aiyohyun
aiyohyun
·
2021-10-22
Good
非常抱歉，此主贴已删除
看
1,998
回复
1
点赞
5
编组 21备份 2
分享
举报
aiyohyun
aiyohyun
·
2021-10-21
Ok
3 Biotech Stocks That Are Ridiculously Overpriced
Beauty is in the eye of the beholder -- and, in many cases, so is the appropriate valuation of a sto
3 Biotech Stocks That Are Ridiculously Overpriced
看
2,647
回复
1
点赞
1
编组 21备份 2
分享
举报
aiyohyun
aiyohyun
·
2021-10-20
Ok
非常抱歉，此主贴已删除
看
1,676
回复
2
点赞
8
编组 21备份 2
分享
举报
aiyohyun
aiyohyun
·
2021-10-19
Okk
Disney+ magic fades: Barclays downgrades Walt Disney after three years
Walt Disney's stock received a rare Wall Street downgrade on Monday, as Barclays called for bold cha
Disney+ magic fades: Barclays downgrades Walt Disney after three years
看
2,153
回复
1
点赞
7
编组 21备份 2
分享
举报
aiyohyun
aiyohyun
·
2021-10-17
Ok
非常抱歉，此主贴已删除
看
3,494
回复
1
点赞
4
编组 21备份 2
分享
举报
aiyohyun
aiyohyun
·
2021-10-15
Ok
非常抱歉，此主贴已删除
看
1,675
回复
1
点赞
7
编组 21备份 2
分享
举报
aiyohyun
aiyohyun
·
2021-10-14
Ok
Why NRx Pharmaceuticals Stock Is Jumping Again on Thursday
New clinical trial results bode well for aviptadil in treating critically ill COVID-19 patients.
Why NRx Pharmaceuticals Stock Is Jumping Again on Thursday
看
2,670
回复
1
点赞
1
编组 21备份 2
分享
举报
aiyohyun
aiyohyun
·
2021-10-13
Ok
非常抱歉，此主贴已删除
看
1,866
回复
1
点赞
3
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3582936698066263","uuid":"3582936698066263","gmtCreate":1619847210575,"gmtModify":1619890947066,"name":"aiyohyun","pinyin":"aiyohyun","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/5efe05924fc38dd8db647c314e32c5b2","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":18,"headSize":303,"tweetSize":217,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.06.10","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"海外","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":858879478,"gmtCreate":1635040396980,"gmtModify":1635040513336,"author":{"id":"3582936698066263","authorId":"3582936698066263","name":"aiyohyun","avatar":"https://static.tigerbbs.com/5efe05924fc38dd8db647c314e32c5b2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582936698066263","authorIdStr":"3582936698066263"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/858879478","repostId":"1174514229","repostType":4,"repost":{"id":"1174514229","kind":"news","pubTimestamp":1635035471,"share":"https://www.laohu8.com/m/news/1174514229?lang=&edition=full","pubTime":"2021-10-24 08:31","market":"us","language":"en","title":"US IPO Week Ahead: Semiconductors, energy storage, designer apparel, and more in a 12 IPO week","url":"https://stock-news.laohu8.com/highlight/detail?id=1174514229","media":"Renaissance Capital","summary":"The IPO market continues to stay busy with 12 IPOs schedule to raise $6.8 billion in the week ahead.","content":"<p>The IPO market continues to stay busy with 12 IPOs schedule to raise $6.8 billion in the week ahead.</p>\n<p>Semiconductor foundry <b>GlobalFoundries</b>(GFS) plans to raise $2.4 billion at a $24.6 billion market cap. Backed by Abu Dhabi’s Mubadala, US-based GlobalFoundries is one of the world’s leading specialty semiconductor foundries. Unprofitable with lumpy growth, the company states that it is the only scaled pure-play foundry with a global footprint that is not based in China.</p>\n<p>Enterprise cloud data management platform <b>Informatica</b>(INFA) plans to raise $885 million at an $8.7 billion market cap. This company provides data integration services on its AI-powered platform to over 5,700 customers through both licenses and subscriptions. Although it will be highly leveraged post-IPO, Informatica is a recognized leader in the global data management market and saw strong subscription ARR growth in the 1H21.</p>\n<p>Energy storage provider <b>Fluence Energy</b>(FLNC) plans to raise $698 million at a $3.8 billion market cap. Formed by Siemens and AES, this company sells energy storage products and services to utilities, independent power producers, project developers, and commercial and industrial customers. Fast growing but unprofitable, Fluence Energy deployed 942 MW of storage products as of 6/30/21.</p>\n<p>Revenue cycle management platform <b>Ensemble Health Partners</b>(ENSB) plans to raise $605 million at a $3.6 billion market cap. This platform provides revenue cycle management solutions to the healthcare industry. Profitable with accelerating growth in the 1H21, Ensemble Health has over $20 billion in annual client net patient revenue under management.</p>\n<p>Hiring solutions provider <b>HireRight Holdings</b>(HRT) plans to raise $500 million at a $1.8 billion market cap. This company provides background checks, verification, identification, monitoring, and drug and health screening services to over 40,000 customers. HireRight was profitable on an EBIT basis in the 1H21, though cash flow swung negative.</p>\n<p>Online education marketplace <b>Udemy</b>(UDMY) plans to raise $406 million at a $4.3 billion market cap. This education platform provides over 183,000 courses in 75 languages to over 44 million customers in over 180 countries. Growing but unprofitable, Udemy has registered more than 73 million users since its inception.</p>\n<p>Chinese drug in-licensor <b>LianBio</b>(LIAN) plans to raise $325 million at a $1.8 billion market cap. Focused on China and other Asian markets, this biopharmaceutical company develops and commercializes drugs for a variety of indications. LianBio’s pipeline currently consists of nine product candidates across five different therapeutics areas.</p>\n<p><b>Rent the Runway</b>(RENT) plans to raise $293 million at a $1.4 billion market cap. This apparel rental company originally focused on a-la-carte rentals of dresses for events, but has gradually transitioned to mostly generating revenue from monthly subscription boxes. While the company has seen active subscribers and revenue rebound in the last two quarters, it is unprofitable and leveraged post-IPO.</p>\n<p>Aesthetic medical device maker <b>Candela Medical</b>(CDLA) plans to raise $250 million at a $1.7 billion market cap. Selling products directly in 18 countries and indirectly in 66 countries, this company develops medical devices for elective aesthetic procedures. Despite being hard hit by the pandemic, Candela Medical saw strong growth and turned profitable in the 1H21.</p>\n<p>Fire pit brand <b>Solo Brands</b>(DTC) plans to raise $200 million at a $1.5 billion market cap. Solo Brands sells fire pits, camp stoves, and other outdoor gear through its DTC platform. Fast growing and profitable, this outdoor e-commerce has an installed base of more than 2.3 million customers.</p>\n<p>Body contouring provider <b>AirSculpt Technologies</b>(AIRS) plans to raise $160 million at an $886 million market cap. This company provides minimally-invasive body contouring procedures through 16 centers across 13 states in the US. AirSculpt Technologies is profitable with solid growth, and has seen an increase in same-center case volume as a result of lessening effects of COVID-19.</p>\n<p>Technology firm <b>Arteris</b>(AIP) plans to raise $75 million at a $555 million market cap. This technology company develops and licenses interconnect intellectual property that manages the on-chip communications in System-on-Chip semiconductor devices. Arteris is unprofitable but saw growth accelerate in the 1H21.</p>\n<p><img src=\"https://static.tigerbbs.com/99c3b0173e59f4e69ff484c12bd137e7\" tg-width=\"1270\" tg-height=\"704\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/64e34b3c49a856e99ba64a2d57410844\" tg-width=\"1272\" tg-height=\"582\" referrerpolicy=\"no-referrer\"></p>\n<p>Street research is expected for six companies, and lock-up periods will be expiring for up to 12 companies.</p>\n<p><b>IPO Market Snapshot</b></p>\n<p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 10/22/21, the Renaissance IPO Index was up 8.2% year-to-date, while the S&P 500 was up 21.1%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Moderna (MRNA). The Renaissance International IPO Index was down 15.8% year-to-date, while the ACWX was up 9.1%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Meituan-Dianping and SoftBank.</p>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: Semiconductors, energy storage, designer apparel, and more in a 12 IPO week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: Semiconductors, energy storage, designer apparel, and more in a 12 IPO week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-24 08:31 GMT+8 <a href=https://www.renaissancecapital.com/IPO-Center/News/87676/US-IPO-Week-Ahead-Semiconductors-energy-storage-designer-apparel-and-more-i><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The IPO market continues to stay busy with 12 IPOs schedule to raise $6.8 billion in the week ahead.\nSemiconductor foundry GlobalFoundries(GFS) plans to raise $2.4 billion at a $24.6 billion market ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/87676/US-IPO-Week-Ahead-Semiconductors-energy-storage-designer-apparel-and-more-i\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UDMY":"Udemy, Inc.",".IXIC":"NASDAQ Composite","HRT":"HireRight Holdings Corp.","INFA":"Informatica Inc.","AIRS":"Airsculpt Technologies","GFS":"GLOBALFOUNDRIES Inc.","AIP":"Arteris, Inc.",".DJI":"道琼斯","RENT":"Rent the Runway, Inc.",".SPX":"S&P 500 Index","FLNC":"Fluence Energy, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/87676/US-IPO-Week-Ahead-Semiconductors-energy-storage-designer-apparel-and-more-i","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174514229","content_text":"The IPO market continues to stay busy with 12 IPOs schedule to raise $6.8 billion in the week ahead.\nSemiconductor foundry GlobalFoundries(GFS) plans to raise $2.4 billion at a $24.6 billion market cap. Backed by Abu Dhabi’s Mubadala, US-based GlobalFoundries is one of the world’s leading specialty semiconductor foundries. Unprofitable with lumpy growth, the company states that it is the only scaled pure-play foundry with a global footprint that is not based in China.\nEnterprise cloud data management platform Informatica(INFA) plans to raise $885 million at an $8.7 billion market cap. This company provides data integration services on its AI-powered platform to over 5,700 customers through both licenses and subscriptions. Although it will be highly leveraged post-IPO, Informatica is a recognized leader in the global data management market and saw strong subscription ARR growth in the 1H21.\nEnergy storage provider Fluence Energy(FLNC) plans to raise $698 million at a $3.8 billion market cap. Formed by Siemens and AES, this company sells energy storage products and services to utilities, independent power producers, project developers, and commercial and industrial customers. Fast growing but unprofitable, Fluence Energy deployed 942 MW of storage products as of 6/30/21.\nRevenue cycle management platform Ensemble Health Partners(ENSB) plans to raise $605 million at a $3.6 billion market cap. This platform provides revenue cycle management solutions to the healthcare industry. Profitable with accelerating growth in the 1H21, Ensemble Health has over $20 billion in annual client net patient revenue under management.\nHiring solutions provider HireRight Holdings(HRT) plans to raise $500 million at a $1.8 billion market cap. This company provides background checks, verification, identification, monitoring, and drug and health screening services to over 40,000 customers. HireRight was profitable on an EBIT basis in the 1H21, though cash flow swung negative.\nOnline education marketplace Udemy(UDMY) plans to raise $406 million at a $4.3 billion market cap. This education platform provides over 183,000 courses in 75 languages to over 44 million customers in over 180 countries. Growing but unprofitable, Udemy has registered more than 73 million users since its inception.\nChinese drug in-licensor LianBio(LIAN) plans to raise $325 million at a $1.8 billion market cap. Focused on China and other Asian markets, this biopharmaceutical company develops and commercializes drugs for a variety of indications. LianBio’s pipeline currently consists of nine product candidates across five different therapeutics areas.\nRent the Runway(RENT) plans to raise $293 million at a $1.4 billion market cap. This apparel rental company originally focused on a-la-carte rentals of dresses for events, but has gradually transitioned to mostly generating revenue from monthly subscription boxes. While the company has seen active subscribers and revenue rebound in the last two quarters, it is unprofitable and leveraged post-IPO.\nAesthetic medical device maker Candela Medical(CDLA) plans to raise $250 million at a $1.7 billion market cap. Selling products directly in 18 countries and indirectly in 66 countries, this company develops medical devices for elective aesthetic procedures. Despite being hard hit by the pandemic, Candela Medical saw strong growth and turned profitable in the 1H21.\nFire pit brand Solo Brands(DTC) plans to raise $200 million at a $1.5 billion market cap. Solo Brands sells fire pits, camp stoves, and other outdoor gear through its DTC platform. Fast growing and profitable, this outdoor e-commerce has an installed base of more than 2.3 million customers.\nBody contouring provider AirSculpt Technologies(AIRS) plans to raise $160 million at an $886 million market cap. This company provides minimally-invasive body contouring procedures through 16 centers across 13 states in the US. AirSculpt Technologies is profitable with solid growth, and has seen an increase in same-center case volume as a result of lessening effects of COVID-19.\nTechnology firm Arteris(AIP) plans to raise $75 million at a $555 million market cap. This technology company develops and licenses interconnect intellectual property that manages the on-chip communications in System-on-Chip semiconductor devices. Arteris is unprofitable but saw growth accelerate in the 1H21.\n\nStreet research is expected for six companies, and lock-up periods will be expiring for up to 12 companies.\nIPO Market Snapshot\nThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 10/22/21, the Renaissance IPO Index was up 8.2% year-to-date, while the S&P 500 was up 21.1%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Moderna (MRNA). The Renaissance International IPO Index was down 15.8% year-to-date, while the ACWX was up 9.1%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Meituan-Dianping and SoftBank.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9,"AIP":0.9,"AIRS":0.9,"CDLA":0.9,"DTC":0.9,"ENSB":0.9,"FLNC":0.9,"GFS":0.9,"HRT":0.9,"INFA":0.9,"LIAN":0.9,"RENT":0.9,"UDMY":0.9}},"isVote":1,"tweetType":1,"viewCount":2050,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":858029525,"gmtCreate":1634954585432,"gmtModify":1634954585819,"author":{"id":"3582936698066263","authorId":"3582936698066263","name":"aiyohyun","avatar":"https://static.tigerbbs.com/5efe05924fc38dd8db647c314e32c5b2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582936698066263","authorIdStr":"3582936698066263"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/858029525","repostId":"1172683205","repostType":4,"isVote":1,"tweetType":1,"viewCount":2737,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":851300603,"gmtCreate":1634867328700,"gmtModify":1634867328828,"author":{"id":"3582936698066263","authorId":"3582936698066263","name":"aiyohyun","avatar":"https://static.tigerbbs.com/5efe05924fc38dd8db647c314e32c5b2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582936698066263","authorIdStr":"3582936698066263"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/851300603","repostId":"2177462128","repostType":4,"isVote":1,"tweetType":1,"viewCount":1998,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853336505,"gmtCreate":1634773020125,"gmtModify":1634773020534,"author":{"id":"3582936698066263","authorId":"3582936698066263","name":"aiyohyun","avatar":"https://static.tigerbbs.com/5efe05924fc38dd8db647c314e32c5b2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582936698066263","authorIdStr":"3582936698066263"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/853336505","repostId":"1151911991","repostType":4,"repost":{"id":"1151911991","kind":"news","pubTimestamp":1634728904,"share":"https://www.laohu8.com/m/news/1151911991?lang=&edition=full","pubTime":"2021-10-20 19:21","market":"us","language":"en","title":"3 Biotech Stocks That Are Ridiculously Overpriced","url":"https://stock-news.laohu8.com/highlight/detail?id=1151911991","media":"Motley Fool","summary":"Beauty is in the eye of the beholder -- and, in many cases, so is the appropriate valuation of a sto","content":"<p>Beauty is in the eye of the beholder -- and, in many cases, so is the appropriate valuation of a stock. One investor might view a stock as overvalued, while another investor sees it as relatively well priced.</p>\n<p>We asked three Motley Fool contributors which biotech stocks they think are ridiculously overpriced right now. Here's why they picked <b>Cassava Sciences</b>(NASDAQ:SAVA),<b>Ocugen</b>(NASDAQ:OCGN), and <b>Moderna</b>(NASDAQ:MRNA).</p>\n<p>This biotech isn't worth the trouble</p>\n<p><b>Prosper Junior Bakiny(Cassava Sciences):</b>Investors have been flocking to this clinical-stage biotech all year long, pushing its share price up by well over 600%. It's still barely into the realm of mid-cap status, though, with a market cap of roughly $2 billion as of this writing.</p>\n<p>Cassava Sciences is hardly worth that much, though.</p>\n<p>It's is currently developing Simufilam for the treatment of Alzheimer's disease. Positive results from a pair of clinical trials -- coupled with the controversial approval of <b>Biogen</b>'s Aduhelm earlier this year -- have helped the company's stock perform as well as it has this year.</p>\n<p>But there are some reasons to worry. First, many companies have tried to develop effective drugs directed at the underlying causes of Alzheimer's disease. Nearly all of them failed, even after successful phase 2 studies.</p>\n<p>Even the data from Biogen's pivotal trial for Aduhelm wasn't that convincing. That's why the Food and Drug Administration is insisting on a post-approval confirmatory study for the medicine. It could be taken off the market if it fails to prove that actually helps Alzheimer's patients.</p>\n<p>Of course, just because others failed to develop an effective treatment for this condition doesn't mean Cassava Sciences will too. The point is, investors should view even the positive results Simufilam has produced so far with a healthy dose of skepticism.</p>\n<p>Results from a 12-month open-label study of Simufilam weren't that impressive. Then there is the citizen petition that New York-based law firm Labaton Sucharow filed with the FDA requesting that the agency halt clinical trials featuring Simufilam. Labaton Sucharow is representing clients with short positions in the stock, so there are some financial incentives for it to target Cassava. Still, this dark cloud will continue to hover above the biotech for a while.</p>\n<p>Add these to the other headwinds that Cassava Sciences could run into, including the very real possibility that Simufilam will fail miserably in its phase 3 clinical trials or that it will encounter regulatory setbacks, and this biotech stock looks far too risky to invest in, even at current levels.</p>\n<p><b>Ocugen is too risky to take a chance on</b></p>\n<p><b>David Jagielski(Ocugen):</b>This company became popular among retail investors this year based on the hopes that it will be the next COVID-19 vaccine stock to make it big. There's just one problem: Ocugen's success in that regard will hinge on the approval of Covaxin, which it's co-developing with Indian biotech company Bharat Biotech.</p>\n<p>Ocugen announced in June that it would pursue a Biologics License Application for its COVID-19 vaccine candidate in the U.S., based on a recommendation from the Food and Drug Administration. That involves a longer process than getting an Emergency Use Authorization, and implies that the agency may have been unwilling to grant emergency approval for the vaccine.</p>\n<p>There was more positive news last week when India granted Emergency Use Authorization for Covaxinto be used to inoculate children ages 2 to 18. Unfortunately, that doesn't mean anything for Ocugen -- it only shares in the profits that the vaccine makes in Canada and the U.S.</p>\n<p>But even though that good news out of India will have no notable impact on Ocugen's business, its stock price jumped anyway, topping the $10 mark for the first time in months. The performance of the company and the stock have simply not been connected. Through the first six months of this year, Ocugen has reported <i>no revenue</i>. Yet its shares have risen by more than 350% year to date.</p>\n<p>The good news is that there is still hope for the business beyond just its COVID-19 vaccine. The company is moving forward on its gene-therapy treatment, OCU400, and it plans to begin clinical studies on it later this year. However, the human trials phase of OCU400's development, even if it's ultimately successful, will take years.</p>\n<p>Given its market cap of $1.6 billion, I think that investors are taking on a ton of risk by buying shares of Ocugen. My view is that this is akin to gambling onpenny stocks, except in those cases, at least, valuations can be incredibly low. In Ocugen's case, the stock may have limited upside.</p>\n<p>A great company that's just too expensive</p>\n<p><b>Keith Speights(Moderna)</b>: Most of the critiques that Prosper and David had for Cassava and Ocugen don't apply to Moderna at all. The company already has a huge blockbuster on the market with its COVID-19 vaccine. It's rolling in profits as sales for the vaccine continue to soar.</p>\n<p>Moderna even has a promising pipeline. It hopes to soon advance cytomegalovirus (CMV) vaccine candidate mRNA-1647 into late-stage testing. The company is evaluating an experimental flu vaccine in early-stage testing and hopes to develop a combination COVID-19/flu vaccine. In total, the company has 17 clinical-stage programs.</p>\n<p>I think that Moderna's messenger RNA (mRNA) platform could produce many blockbuster vaccines and therapies over the coming decades. My view is that it's a great company. However, I also think that its shares are just too expensive now.</p>\n<p>Some might point to Moderna's forward price-to-earnings multiple of 11.2 as evidence that I'm dead wrong about the stock being overvalued. However, the problem with this metric is that it only looks one year into the future. Moderna's CEO has predicted that the pandemic could effectively end by late 2022. If he's right, I suspect that the company's revenue and earnings could fall off significantly after that.</p>\n<p>Remember that Moderna's enormous success so far has resulted from a two-dose initial regimen of its COVID-19 vaccine. Boosters of that vaccine will only require one shot. More importantly, there's uncertainty about how frequently boosters will be needed. Governments around the world could also become more price-conscious about what they'll pay for COVID-19 vaccines in a post-pandemic environment.</p>\n<p>Perhaps things will unfold in a way that justifies Moderna's current valuation. For now, though, I think there are more outcomes that could cause this stock to fall than there are catalysts that could make it soar again.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Biotech Stocks That Are Ridiculously Overpriced</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Biotech Stocks That Are Ridiculously Overpriced\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-20 19:21 GMT+8 <a href=https://www.fool.com/investing/2021/10/20/3-biotech-stocks-that-are-ridiculously-overpriced/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Beauty is in the eye of the beholder -- and, in many cases, so is the appropriate valuation of a stock. One investor might view a stock as overvalued, while another investor sees it as relatively well...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/20/3-biotech-stocks-that-are-ridiculously-overpriced/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","SAVA":"Cassava Sciences Inc","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/10/20/3-biotech-stocks-that-are-ridiculously-overpriced/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151911991","content_text":"Beauty is in the eye of the beholder -- and, in many cases, so is the appropriate valuation of a stock. One investor might view a stock as overvalued, while another investor sees it as relatively well priced.\nWe asked three Motley Fool contributors which biotech stocks they think are ridiculously overpriced right now. Here's why they picked Cassava Sciences(NASDAQ:SAVA),Ocugen(NASDAQ:OCGN), and Moderna(NASDAQ:MRNA).\nThis biotech isn't worth the trouble\nProsper Junior Bakiny(Cassava Sciences):Investors have been flocking to this clinical-stage biotech all year long, pushing its share price up by well over 600%. It's still barely into the realm of mid-cap status, though, with a market cap of roughly $2 billion as of this writing.\nCassava Sciences is hardly worth that much, though.\nIt's is currently developing Simufilam for the treatment of Alzheimer's disease. Positive results from a pair of clinical trials -- coupled with the controversial approval of Biogen's Aduhelm earlier this year -- have helped the company's stock perform as well as it has this year.\nBut there are some reasons to worry. First, many companies have tried to develop effective drugs directed at the underlying causes of Alzheimer's disease. Nearly all of them failed, even after successful phase 2 studies.\nEven the data from Biogen's pivotal trial for Aduhelm wasn't that convincing. That's why the Food and Drug Administration is insisting on a post-approval confirmatory study for the medicine. It could be taken off the market if it fails to prove that actually helps Alzheimer's patients.\nOf course, just because others failed to develop an effective treatment for this condition doesn't mean Cassava Sciences will too. The point is, investors should view even the positive results Simufilam has produced so far with a healthy dose of skepticism.\nResults from a 12-month open-label study of Simufilam weren't that impressive. Then there is the citizen petition that New York-based law firm Labaton Sucharow filed with the FDA requesting that the agency halt clinical trials featuring Simufilam. Labaton Sucharow is representing clients with short positions in the stock, so there are some financial incentives for it to target Cassava. Still, this dark cloud will continue to hover above the biotech for a while.\nAdd these to the other headwinds that Cassava Sciences could run into, including the very real possibility that Simufilam will fail miserably in its phase 3 clinical trials or that it will encounter regulatory setbacks, and this biotech stock looks far too risky to invest in, even at current levels.\nOcugen is too risky to take a chance on\nDavid Jagielski(Ocugen):This company became popular among retail investors this year based on the hopes that it will be the next COVID-19 vaccine stock to make it big. There's just one problem: Ocugen's success in that regard will hinge on the approval of Covaxin, which it's co-developing with Indian biotech company Bharat Biotech.\nOcugen announced in June that it would pursue a Biologics License Application for its COVID-19 vaccine candidate in the U.S., based on a recommendation from the Food and Drug Administration. That involves a longer process than getting an Emergency Use Authorization, and implies that the agency may have been unwilling to grant emergency approval for the vaccine.\nThere was more positive news last week when India granted Emergency Use Authorization for Covaxinto be used to inoculate children ages 2 to 18. Unfortunately, that doesn't mean anything for Ocugen -- it only shares in the profits that the vaccine makes in Canada and the U.S.\nBut even though that good news out of India will have no notable impact on Ocugen's business, its stock price jumped anyway, topping the $10 mark for the first time in months. The performance of the company and the stock have simply not been connected. Through the first six months of this year, Ocugen has reported no revenue. Yet its shares have risen by more than 350% year to date.\nThe good news is that there is still hope for the business beyond just its COVID-19 vaccine. The company is moving forward on its gene-therapy treatment, OCU400, and it plans to begin clinical studies on it later this year. However, the human trials phase of OCU400's development, even if it's ultimately successful, will take years.\nGiven its market cap of $1.6 billion, I think that investors are taking on a ton of risk by buying shares of Ocugen. My view is that this is akin to gambling onpenny stocks, except in those cases, at least, valuations can be incredibly low. In Ocugen's case, the stock may have limited upside.\nA great company that's just too expensive\nKeith Speights(Moderna): Most of the critiques that Prosper and David had for Cassava and Ocugen don't apply to Moderna at all. The company already has a huge blockbuster on the market with its COVID-19 vaccine. It's rolling in profits as sales for the vaccine continue to soar.\nModerna even has a promising pipeline. It hopes to soon advance cytomegalovirus (CMV) vaccine candidate mRNA-1647 into late-stage testing. The company is evaluating an experimental flu vaccine in early-stage testing and hopes to develop a combination COVID-19/flu vaccine. In total, the company has 17 clinical-stage programs.\nI think that Moderna's messenger RNA (mRNA) platform could produce many blockbuster vaccines and therapies over the coming decades. My view is that it's a great company. However, I also think that its shares are just too expensive now.\nSome might point to Moderna's forward price-to-earnings multiple of 11.2 as evidence that I'm dead wrong about the stock being overvalued. However, the problem with this metric is that it only looks one year into the future. Moderna's CEO has predicted that the pandemic could effectively end by late 2022. If he's right, I suspect that the company's revenue and earnings could fall off significantly after that.\nRemember that Moderna's enormous success so far has resulted from a two-dose initial regimen of its COVID-19 vaccine. Boosters of that vaccine will only require one shot. More importantly, there's uncertainty about how frequently boosters will be needed. Governments around the world could also become more price-conscious about what they'll pay for COVID-19 vaccines in a post-pandemic environment.\nPerhaps things will unfold in a way that justifies Moderna's current valuation. For now, though, I think there are more outcomes that could cause this stock to fall than there are catalysts that could make it soar again.","news_type":1,"symbols_score_info":{"MRNA":0.9,"OCGN":0.9,"SAVA":0.9}},"isVote":1,"tweetType":1,"viewCount":2647,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859168090,"gmtCreate":1634679474039,"gmtModify":1634679474403,"author":{"id":"3582936698066263","authorId":"3582936698066263","name":"aiyohyun","avatar":"https://static.tigerbbs.com/5efe05924fc38dd8db647c314e32c5b2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582936698066263","authorIdStr":"3582936698066263"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/859168090","repostId":"1113211293","repostType":4,"isVote":1,"tweetType":1,"viewCount":1676,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":850601124,"gmtCreate":1634582595053,"gmtModify":1634582595397,"author":{"id":"3582936698066263","authorId":"3582936698066263","name":"aiyohyun","avatar":"https://static.tigerbbs.com/5efe05924fc38dd8db647c314e32c5b2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582936698066263","authorIdStr":"3582936698066263"},"themes":[],"htmlText":"Okk","listText":"Okk","text":"Okk","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/850601124","repostId":"1177726885","repostType":4,"repost":{"id":"1177726885","kind":"news","pubTimestamp":1634568658,"share":"https://www.laohu8.com/m/news/1177726885?lang=&edition=full","pubTime":"2021-10-18 22:50","market":"us","language":"en","title":"Disney+ magic fades: Barclays downgrades Walt Disney after three years","url":"https://stock-news.laohu8.com/highlight/detail?id=1177726885","media":"Reuters","summary":"Walt Disney's stock received a rare Wall Street downgrade on Monday, as Barclays called for bold cha","content":"<p>Walt Disney's stock received a rare Wall Street downgrade on Monday, as Barclays called for bold changes from the media giant to reverse slowing growth at its Disney+ streaming service.</p>\n<p>Disney Chief Executive Officer Bob Chapek last month hinted at a slowdown in Disney+, saying fourth-quarter global paid subscribers will grow by \"low single digit\" millions compared with a rise of 58.5 million in the previous three months.</p>\n<p>Disney+, which has one of the richest portfolios of media content, had a blockbuster launch in 2019; it attracted new subscribers with its hit \"Star Wars\" and \"Avengers\" franchises.</p>\n<p>Rival streaming platforms such as Netflix Inc, Apple TV+ and Amazon Prime Video have had a different approach. They invested heavily on original content to draw in subscribers.</p>\n<p>\"While the company (Disney) appears to be targeting one new piece of content a week, not every piece of content has the same franchise value or visibility,\" Barclays analyst Kannan Venkateshwar said.</p>\n<p>Barclays also said the slowdown in Disney+ subscribers could not be solely attributed to a pull forward in additions in 2020, when streaming platforms gained popularity as people hunkering down at home sought entertainment.</p>\n<p>To achieve its target of 230 million to 260 million Disney+ subscribers by the end of fiscal 2024, Disney will need to more than double its current pace of growth to at least the same level as Netflix, according to Barclays.</p>\n<p>Netflix, which is due to report its quarterly results on Tuesday, had 209 million subscribers as of the quarter ended June. Disney+ had 116 million paying customers.</p>\n<p>Disney shares, which have not been downgraded by any brokerage so far this year, fell about 2% in early trading.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Disney+ magic fades: Barclays downgrades Walt Disney after three years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDisney+ magic fades: Barclays downgrades Walt Disney after three years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-18 22:50 GMT+8 <a href=https://finance.yahoo.com/news/disney-magic-fades-barclays-downgrades-142636250.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Walt Disney's stock received a rare Wall Street downgrade on Monday, as Barclays called for bold changes from the media giant to reverse slowing growth at its Disney+ streaming service.\nDisney Chief ...</p>\n\n<a href=\"https://finance.yahoo.com/news/disney-magic-fades-barclays-downgrades-142636250.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DIS":"迪士尼"},"source_url":"https://finance.yahoo.com/news/disney-magic-fades-barclays-downgrades-142636250.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1177726885","content_text":"Walt Disney's stock received a rare Wall Street downgrade on Monday, as Barclays called for bold changes from the media giant to reverse slowing growth at its Disney+ streaming service.\nDisney Chief Executive Officer Bob Chapek last month hinted at a slowdown in Disney+, saying fourth-quarter global paid subscribers will grow by \"low single digit\" millions compared with a rise of 58.5 million in the previous three months.\nDisney+, which has one of the richest portfolios of media content, had a blockbuster launch in 2019; it attracted new subscribers with its hit \"Star Wars\" and \"Avengers\" franchises.\nRival streaming platforms such as Netflix Inc, Apple TV+ and Amazon Prime Video have had a different approach. They invested heavily on original content to draw in subscribers.\n\"While the company (Disney) appears to be targeting one new piece of content a week, not every piece of content has the same franchise value or visibility,\" Barclays analyst Kannan Venkateshwar said.\nBarclays also said the slowdown in Disney+ subscribers could not be solely attributed to a pull forward in additions in 2020, when streaming platforms gained popularity as people hunkering down at home sought entertainment.\nTo achieve its target of 230 million to 260 million Disney+ subscribers by the end of fiscal 2024, Disney will need to more than double its current pace of growth to at least the same level as Netflix, according to Barclays.\nNetflix, which is due to report its quarterly results on Tuesday, had 209 million subscribers as of the quarter ended June. Disney+ had 116 million paying customers.\nDisney shares, which have not been downgraded by any brokerage so far this year, fell about 2% in early trading.","news_type":1,"symbols_score_info":{"DIS":0.9}},"isVote":1,"tweetType":1,"viewCount":2153,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":827250866,"gmtCreate":1634483388359,"gmtModify":1634483388808,"author":{"id":"3582936698066263","authorId":"3582936698066263","name":"aiyohyun","avatar":"https://static.tigerbbs.com/5efe05924fc38dd8db647c314e32c5b2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582936698066263","authorIdStr":"3582936698066263"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/827250866","repostId":"2175146556","repostType":4,"isVote":1,"tweetType":1,"viewCount":3494,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":824299115,"gmtCreate":1634312513434,"gmtModify":1634312513781,"author":{"id":"3582936698066263","authorId":"3582936698066263","name":"aiyohyun","avatar":"https://static.tigerbbs.com/5efe05924fc38dd8db647c314e32c5b2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582936698066263","authorIdStr":"3582936698066263"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/824299115","repostId":"2175117376","repostType":4,"isVote":1,"tweetType":1,"viewCount":1675,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":825234430,"gmtCreate":1634226446182,"gmtModify":1634226446334,"author":{"id":"3582936698066263","authorId":"3582936698066263","name":"aiyohyun","avatar":"https://static.tigerbbs.com/5efe05924fc38dd8db647c314e32c5b2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582936698066263","authorIdStr":"3582936698066263"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/825234430","repostId":"1151136903","repostType":4,"repost":{"id":"1151136903","kind":"news","pubTimestamp":1634225065,"share":"https://www.laohu8.com/m/news/1151136903?lang=&edition=full","pubTime":"2021-10-14 23:24","market":"us","language":"en","title":"Why NRx Pharmaceuticals Stock Is Jumping Again on Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=1151136903","media":"Motley Fool","summary":"New clinical trial results bode well for aviptadil in treating critically ill COVID-19 patients.","content":"<p><b>Key Points</b></p>\n<ul>\n <li>An infectious-disease journal published results from a clinical trial with NRx Pharmaceuticals' lead candidate aviptadil.</li>\n <li>Aviptadil is in development for the treatment of respiratory failure related to severe COVID infection.</li>\n <li>The peer-reviewed results were positive but hardly sufficient to support a request for Emergency Use Authorization from the FDA.</li>\n</ul>\n<p><b>What happened</b></p>\n<p>Shares of <b>NRx Pharmaceuticals</b>(NASDAQ:NRXP) are rising sharply for the second time this week. On Tuesday, the stock jumped higher after the company relayed some positive regulatory developments. Today, investors are excited about clinical trial results for aviptadil, a potential new treatment for respiratory failure caused by COVID-19. The biotech stock was up 33.8% as of 10:54 a.m. EDT on Thursday.</p>\n<p><b>So what</b></p>\n<p>This morning, an infectious-disease journal published peer-reviewed results of an open-label trial with aviptadil and critically ill COVID patients. An impressive 81% of patients treated with aviptadil survived at least 60 days compared to just 21% of patients given standard care.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e2822fcb875474824949ad943caf5b99\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p>The number of severe COVID infections has dropped considerably since the study, but there could still be enough to drive significant sales. As a clinical-stage company without any approved drugs generating revenue, even modest sales of aviptadil could lead to market-beating gains for NRx Pharmaceuticals investors.</p>\n<p><b>Now what</b></p>\n<p>Unfortunately, we still don't know when NRx Pharmaceuticals will get a chance to launch aviptadil. The results presented today are interesting, but there's more work to do.</p>\n<p>Today's announcement came from an open-label trial conducted in a single hospital system without any randomization. Investigators simply treated 21 consecutive eligible patients who were admitted to a single hospital system in Houston during the summer of 2020.</p>\n<p>In place of a placebo, investigators used patients with similar comorbidities admitted before and after the group who were treated with aviptadil. These results are interesting. On their own, though, they won't be sufficient to support an Emergency Use Authorization request.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why NRx Pharmaceuticals Stock Is Jumping Again on Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy NRx Pharmaceuticals Stock Is Jumping Again on Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-14 23:24 GMT+8 <a href=https://www.fool.com/investing/2021/10/14/why-nrx-pharmaceuticals-is-jumpng-again-on-thursda/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nAn infectious-disease journal published results from a clinical trial with NRx Pharmaceuticals' lead candidate aviptadil.\nAviptadil is in development for the treatment of respiratory ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/14/why-nrx-pharmaceuticals-is-jumpng-again-on-thursda/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NRXP":"NRX Pharmaceuticals Inc."},"source_url":"https://www.fool.com/investing/2021/10/14/why-nrx-pharmaceuticals-is-jumpng-again-on-thursda/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151136903","content_text":"Key Points\n\nAn infectious-disease journal published results from a clinical trial with NRx Pharmaceuticals' lead candidate aviptadil.\nAviptadil is in development for the treatment of respiratory failure related to severe COVID infection.\nThe peer-reviewed results were positive but hardly sufficient to support a request for Emergency Use Authorization from the FDA.\n\nWhat happened\nShares of NRx Pharmaceuticals(NASDAQ:NRXP) are rising sharply for the second time this week. On Tuesday, the stock jumped higher after the company relayed some positive regulatory developments. Today, investors are excited about clinical trial results for aviptadil, a potential new treatment for respiratory failure caused by COVID-19. The biotech stock was up 33.8% as of 10:54 a.m. EDT on Thursday.\nSo what\nThis morning, an infectious-disease journal published peer-reviewed results of an open-label trial with aviptadil and critically ill COVID patients. An impressive 81% of patients treated with aviptadil survived at least 60 days compared to just 21% of patients given standard care.\nIMAGE SOURCE: GETTY IMAGES.\nThe number of severe COVID infections has dropped considerably since the study, but there could still be enough to drive significant sales. As a clinical-stage company without any approved drugs generating revenue, even modest sales of aviptadil could lead to market-beating gains for NRx Pharmaceuticals investors.\nNow what\nUnfortunately, we still don't know when NRx Pharmaceuticals will get a chance to launch aviptadil. The results presented today are interesting, but there's more work to do.\nToday's announcement came from an open-label trial conducted in a single hospital system without any randomization. Investigators simply treated 21 consecutive eligible patients who were admitted to a single hospital system in Houston during the summer of 2020.\nIn place of a placebo, investigators used patients with similar comorbidities admitted before and after the group who were treated with aviptadil. These results are interesting. On their own, though, they won't be sufficient to support an Emergency Use Authorization request.","news_type":1,"symbols_score_info":{"NRXP":0.9}},"isVote":1,"tweetType":1,"viewCount":2670,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":822634988,"gmtCreate":1634124599901,"gmtModify":1634124600090,"author":{"id":"3582936698066263","authorId":"3582936698066263","name":"aiyohyun","avatar":"https://static.tigerbbs.com/5efe05924fc38dd8db647c314e32c5b2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582936698066263","authorIdStr":"3582936698066263"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/822634988","repostId":"2175152306","repostType":4,"isVote":1,"tweetType":1,"viewCount":1866,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}